Navigation Links
Experimental Vaginal Gel Doesn't Ward Off HIV
Date:12/4/2008

South African women using Carraguard had no decrease in infections, trial found

THURSDAY, Dec. 4 (HealthDay News) -- A microbicidal vaginal gel called Carraguard doesn't protect women from HIV infection.

That's the conclusion of a study that included more than 6,200 sexually-active, HIV-negative women at three sites in South Africa.

The women were given either Carraguard or a placebo gel and told to use one applicator of gel and a condom each time they had vaginal sex. The women, who were followed for up to two years, visited a clinic every three months to have tests for HIV infection and pregnancy, pelvic examinations, risk reduction counseling, and treatment for curable sexually transmitted diseases and vaginal infections.

The rate of HIV infection among women using Carraguard was 3.3 per 100-woman years, compared with 3.8 per 100-woman years in the placebo group. Rates of self-reported gel use were similar in both groups (96.2 percent Carraguard, 95.9 percent placebo), but applicator testing indicated that actual gel use was much lower (41.1 percent Carraguard, 43.1 percent placebo). Self-reported condom use was 64.1 percent for both groups.

The findings were published in this week's issue of The Lancet.

"This study did not show Carraguard's efficacy in prevention of male-to-female transmission of HIV, although no safety concerns were recorded. Low levels of gel use could have compromised the potential to detect a significant protective effect. Although the results from this and other completed microbicide efficacy trials have been disappointing, the search for female-controlled HIV-prevention methods must continue," wrote researchers from the Population Council in New York City and their colleagues.

Carraguard, a carrageenan-based compound, was developed by the Population Council.

In an accompanying comment, Dr. Willard Cates and Dr. Paul Feldblum, of Family Health International in North Carolina, wrote that no single method of HIV prevention will be adequate.

"Rather a combination of partly effective prevention approaches will be bundled into packages targeted to specific populations. This bundling will involve behavioral, biomedical, and structural interventions, each designed to reinforce the effect of the other. The cumulative influence of combination prevention is our hope for thwarting the spread of HIV," they said.

More information

The U.S. Centers for Disease Control and Prevention has more about HIV infection risk factors and prevention.



-- Robert Preidt



SOURCE: The Lancet, news release, Dec. 5, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells
2. Experimental Antidepressants Offer Faster Relief
3. Experimental drug shows promise in advanced kidney cancer
4. Experimental drug boosts survival in recurrent ovarian cancer
5. Experimental cancer pharmaceuticals under trial
6. Experimental Drug Fails Against Heart Failure
7. Experimental Drug Fights Prostate Cancer
8. Experimental technique at GUMC offers real-time analysis of breast cancer biopsies
9. Experimental Vaccine Halts Prostate Cancer in Mice
10. Experimental Biology 2008 Todays Research: Tomorrows Health, April 5-9
11. 52 minority scientists receive travel fellowships to Experimental Biology 2008
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Vaginal Gel Doesn't Ward Off HIV
(Date:7/20/2017)... Los Angeles, California (PRWEB) , ... July 19, 2017 , ... ... which found that most successful weight loss surgery patients who had received a body ... Angeles Area health and beauty clinic Beverly Hills Physicians (BHP), which provides both types ...
(Date:7/20/2017)... ... July 20, 2017 , ... “Fidget”: a fun-filled, action-packed memoir ... public high school music and drama teacher who was a summa cum laude graduate ... a “Teacher of the Year” award. After her retirement from public school, Lynn continued ...
(Date:7/18/2017)... , ... July 18, 2017 , ... CannaKids, a California ... cannabis oils, announced today that at the WORLDZ Summit, taking place in Hollywood ... on the therapeutic benefits of medical cannabis for both pediatric and adult patients, and ...
(Date:7/18/2017)... VA (PRWEB) , ... July 18, 2017 , ... ... 11) , What Strategic Decisions Do You Need to Consider?, **An FDAnews ...      , 42 CFR Part 11, “Final Rule for Clinical Trials Registration ...
(Date:7/18/2017)... ... July 18, 2017 , ... ... basis, partners with the best medical professionals who offer the most effective and ... medical professional in their network, ensuring that each patient receives prompt and courteous ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... -- Dr. Echenberg, founder of Echenberg Institute, is announcing a new safe and ... painful intercourse and other painful pelvic pain conditions such as pelvic floor ... ... ... -based start-up company, VuVatech LLC, fills a void in the women,s ...
(Date:7/10/2017)... COLUMBIA, S.C. , July 10, 2017 /PRNewswire/ ... product purchasing and patient support services organization serving ... announced today the launch of four significant, value-added ... into market insights, better manage reimbursement and improve ... Ig and factor therapies. ...
(Date:7/5/2017)... July 5, 2017 Wolfmet 3D  printed tungsten collimator manufactured ... physics and manufacturing combine to progress molecular radiotherapy imaging. ... systems are unable to accurately quantify the radiation absorbed by ... regarding the success of this radiotherapy treatment has been available ... ...
Breaking Medicine Technology: